Image
Clinical Issues™

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Meeting Slides

Clinical Practice Guidelines

Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection.

American Association for the Study of Liver Diseases (AASLD)-Infectious Diseases Society of America (IDSA). Clin Infect Dis. 2018;67(10):1477-1492.

The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.

Chalasani N, et al. Hepatology. 2018;67(1):328-357.

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

European Association for the Study of the Liver. J Hepatol. 2017;67(2):370-398.

EASL recommendations on treatment of hepatitis C 2018.

European Association for the Study of the Liver (EASL). J Hepatol. 2018;69(2):461-511.

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO). J Hepatol. 2016;64(6):1388-1402.

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Terrault NA, et al. Hepatology. 2018;67(4):1560-1599.

Clinical Resources

Histological Scoring System for Nonalcoholic Fatty Liver Disease.

Transplant Pathology Internet Services, 2009.

MELD Score (Model for End-Stage Liver Disease) (12 years and older).

MD+CALC online calculator, 2016.

NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score.

MD+CALC online calculator.

Patient Resources

American College of Gastroenterology (ACG) Patient Education and Resource Center.

The ACG website provides a basic overview of chronic liver disease that includes patient-centered podcasts.

American Liver Foundation.

The American Liver Foundation website offers broad-based information and links to additional educational resources and support services for patients living with liver disease.

Centers for Disease Control and Prevention (CDC).

The CDC provides an overview of all forms of viral hepatitis and how to get tested for both hepatitis C virus (HCV) and hepatitis B virus (HBV).

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Health Information Center.

The NIDDK website for NAFLD and nonalcoholic steatohepatitis (NASH) provides comprehensive patient-centered information and resources, including an overview of clinical trial participation.

Suggested Readings

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.

Agarwal K, et al. J Hepatol. 2018;68(4):672-681.

Non-alcoholic fatty liver disease: an expanded review.

Benedict M, Zhang X. World J Hepatol. 2017;9(16):715-732.

NAFLD: a multisystem disease.

Byrne CD, Targher G. J Hepatol. 2015;62(suppl 1):S47-S64.

Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.

Cusi K, et al. Ann Intern Med. 2016;165(5):305-315.

Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis.

Dulai PS, et al. Hepatology. 2017;65(5):1557-1565.

Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.

Dyson JK, et al. J Clin Pathol. 2013;66(12):1033-1045.

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Feld JJ, et al. N Engl J Med. 2014;370(17):1594-1603.

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.

Friedman SL, et al. Hepatology. 2018;67(5):1754-1767.

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.

Grebely J, et al. Lancet Gastroenterol Hepatol. 2018;3(3):153-161.

Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Hannah WN Jr, Harrison SA. Hepatology. 2016;64(6):2234-2243.

Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial.

Kattakuzhy S, et al. Ann Intern Med. 2017;167(5):311-318.

Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.

Lee MH, et al. Hepatology. 2013;58(2):546-554.

Hepatitis B cure: from discovery to regulatory approval.

Lok AS, et al. Hepatology. 2017;66(4):1296-1313.

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial.

Loomba R, et al. Hepatology. 2018;67(2):549-559.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Neuschwander-Tetri BA, et al. Lancet. 2015;385(9972):956-965.

Improved bone and renal safety at 1 year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF): results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B (CHB).

Pan CQ, et al. Hepatology. 2017; 66(suppl 1):482A.

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.

Papatheodoridis GV, et al. Hepatology. 2017;66(5):1444-1453.

The therapeutic landscape of non-alcoholic steatohepatitis.

Perazzo H, Dufour JF. Liver Int. 2017;37(5):634-647.

Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.

Ratziu V, et al. Gastroenterology. 2016;150(5):1147-1159.

Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: year 2 analysis of the phase 2b CENTAUR study.

Ratziu V, et al. J Hepatol. 2018;68(suppl 1):S1-S2.

Management of NAFLD: a stage-based approach.

Rinella ME, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2016;13(4):196-205.

Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Spengler EK, Loomba R. Mayo Clin Proc. 2015;90(9):1233-1246.

The performance of vibration controlled transient elastography in a US cohort of patients with non-alcoholic fatty liver disease.

Tapper EB, et al. Am J Gastroenterol. 2016;111(5):677-684.

Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD.

Tapper EB, Loomba R. Nat Rev Gastroenterol Hepatol. 2018;15(5):274-282.

Challenges to a cure for HBV infection.

Testoni B, et al. Semin Liver Dis. 2017;37(3):231-242.

Marked reduction in the prevalence of hepatitis C viremia among people who inject drugs during 2nd year of the Treatment as Prevention (TraP HepC) program in Iceland.

Tyrfingsson T, et al. J Hepatol. 2018;68(suppl 1):S52

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.

Wong VW, et al. Hepatology. 2010;51(2):454-462.

Global epidemiology of nonalcoholic fatty liver disease- Meta-analytic assessment of prevalence, incidence, and outcomes.

Younossi ZM, et al. Hepatology. 2016;64(1):73-84.

Activity
Clinical Issues™ in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

The Nexus of NASH and Type 2 Diabetes Mellitus

The Emerging Role of the Diabetologist

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

The Changing Landscape of IBD

Emerging Concepts in Patient Management

The Big (& Small) Picture of Nonalcoholic Steatohepatitis

Building Your Understanding to Combat a Growing Problem

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Trends and Updates in IBD

Appraising the Therapeutic Armamentarium in Moderate and Severe Disease

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

Evolving Models of HIV Care (Volume 3)

The Rapid ART Standard of Care: From Evidence to Healthcare Equity

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Case Challenges in HIV Medicine

Benefits, Barriers, & Best Practices in an Advancing Field

Challenges and Opportunities in HIV

Practical Solutions Across the Spectrum of Care

A Critical Appraisal of Non-Invasive Technologies in NASH

Informing the Future of NASH Diagnosis and Assessment

Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Setting a Course for the Optimal Management of IBD

An Interactive Learning Experience

Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up to Date?

A Focus on Clinical Evidence and Guideline Recommendations

Treating Hepatitis C in the Primary Care Setting

A Critical Step Toward HCV Elimination

Honing Clinical Skills in HIV Treatment

Considering the Patient, the Provider, and the Science

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

IBD Journal Club:

Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD

Clinical Issues in COVID-19

Debates and Discussions about Monoclonal Antibody Therapies

Minimizing Patient Risks From COVID-19

An Update on Monoclonal Antibody Therapies

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients

Answering the Call

Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Putting a Spotlight on Systemic Mastocytosis

A Multidisciplinary Look at Early Diagnosis and Management

Clinical Updates in COVID-19

Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment

Is It Systemic Mastocytosis?

Best Practices for Diagnosis and Management

Monoclonal Antibodies for COVID-19

An Update on Best Practices

Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis

Virologic Failure in HIV

An Updated Clinician’s Guide to Assessment and Management

Applying HIV Advances in Practice

What the Pharmacist Needs to Know

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

Pharmacy PrEP Education

A “How To” Series Spanning Policy to Practice

BRIDGE PrEP

Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention

Long-Acting Injectable PrEP:

Bringing HIV Prevention to a New Level

PrEParing to End the Epidemic

Optimizing HIV Prevention in Primary Care

A Call to Action

Monoclonal Antibodies for the Prevention and Treatment of COVID-19

What’s Next

Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis

Answers to Everyday Practice Challenges in HIV Medicine

A Phone-a-Friend CME Series – Volume 2

What’s New in the Management of COVID-19

Incorporating New Data and Updated Guidelines Into Daily Practice

Strengthening Your COVID-19 Management Technique

Exercising Best Practices for Hospitalized Patients